Kenneth S. Cohen to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications Kenneth S. Cohen has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.110
-
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
Score: 0.092
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
Score: 0.018